Each month, Start-Up presents a comprehensive review of young, private life science companies that have received venture funding during the month, including companies in the pharmaceutical, medical device, diagnostic and research instrumentation & reagent sectors.

In contrast to a host of companies pursuing GLP-1 pathway in diabetes, Diabetica is pioneering GIP research. Because there is currently no marketed antagonist to make insulin work better in the body, as Diabetica believes its GIP agonist will, the company hopes that, at the end of the day, it won't be competing with other compounds at all.